• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Societal CDMO Inc.

    4/1/24 5:03:18 PM ET
    $SCTL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SCTL alert in real time by email
    SC 13G 1 sctl13g.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. ___)*

     

     

    Societal CDMO, Inc.

    (Name of Issuer)

     

     

    Common Stock, par value $0.01 per share

    (Title of Class of Securities)

     

     

    75629F109

    (CUSIP Number)

     

     

    March 20, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [X]       Rule 13d-1(b)

     

    [X]       Rule 13d-1(c)

     

    [ ]       Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

     1 

    CUSIP No. 75629F109

     

     

    1.Names of Reporting Persons.


    Beryl Capital Management LLC

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)     X     

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 8,942,946

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 8,942,946

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 8,942,946

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 8.5%

     

    12. Type of Reporting Person (See Instructions) IA, OO

     2 

    CUSIP No. 75629F109

     

     

    1.Names of Reporting Persons.


    Beryl Capital Management LP

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)     X     

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 8,942,946

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 8,942,946

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 8,942,946

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 8.5%

     

    12. Type of Reporting Person (See Instructions) IA, PN

     3 

    CUSIP No. 75629F109

     

     

    1.Names of Reporting Persons.


    Beryl Capital Partners II LP

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)          

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 7,902,957

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 7,902,957

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 7,902,957

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 7.5%

     

    12. Type of Reporting Person (See Instructions) PN

     4 

    CUSIP No. 75629F109

     

    1.Names of Reporting Persons.


    David A. Witkin

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)     X     

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization U.S.A.

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 8,942,946

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 8,942,946

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 8,942,946

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 8.5%

     

    12. Type of Reporting Person (See Instructions) IN, HC

     5 

    CUSIP No. 75629F109

    Item 1.

     

    (a)Name of Issuer

    Societal CDMO, Inc.

     

    (b)Address of Issuer's Principal Executive Offices

    1 E. Uwchlan Ave, Suite 112, Exton, PA 19341

     

    Item 2.

     

    (a)The names of the persons filing this statement are:

    Beryl Capital Management LLC (“Beryl”), Beryl Capital Management LP (“Beryl GP”), Beryl Capital Partners II LP (the “Partnership”) and David A. Witkin (collectively, the “Filers”). Each Filer disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

     

    (b)The principal business office of the Filers is located at:

    225 Avenue I, Suite 205, Redondo Beach, CA 90277

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to the Issuer’s Common Stock, par value $0.01 per share (the "Stock").

     

    (e)The CUSIP number of the Issuer is: 75629F109

     

     

     6 

    CUSIP No. 75629F109

     

    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)[X] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E), as to Beryl and Beryl GP.

     

    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).

     

    (g)[X] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G), as to Mr. Witkin.

     

    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j)[ ] A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J).

     

    (k)[ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution _______________________________________________________________.

     

    Item 4.Ownership.

     

    See Items 5-9 and 11 of the cover page for each Filer.

     

    The percentages reported in this Schedule 13G are based on 105,690,922 shares of Common Stock outstanding as of March 15, 2024, as reported in the Form 10-K filed by the Issuer on March 22, 2024.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Beryl is the investment adviser to the Funds and other accounts. Beryl is the general partner of Beryl GP, which is the general partner of one or more of the Funds. Mr. Witkin is the control person of Beryl.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Material to Be Filed as Exhibits

    Exhibit A Joint Filing Agreement.

    Item 11.Certification of Beryl, Beryl GP and Mr. Witkin.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Certification of the Partnership.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     7 

    CUSIP No. 75629F109

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: April 1, 2024

     

    BERYL CAPITAL MANAGEMENT LLC  

    BERYL CAPITAL MANAGEMENT LP

     

          By: Beryl Capital Management LLC
            General Partner
    By: /s/ Andrew Nelson      
      Andrew Nelson     By: /s/ Andrew Nelson
      Chief Operating Officer and CFO       Andrew Nelson
            Chief Operating Officer and CFO
    BERYL CAPITAL PARTNERS II LP    
         
    By: Beryl Capital Management LP   /s/ David A. Witkin
    General Partner   David A. Witkin
         
    By: Beryl Capital Management LLC    
    General Partner    
         
    By:/s/ Andrew Nelson    
    Andrew Nelson    
    Chief Operating Officer    
     8 

    CUSIP No. 75629F109

     

    EXHIBIT A

     

    AGREEMENT REGARDING JOINT FILING

    OF STATEMENT ON SCHEDULE 13D OR 13G

     

    The undersigned agree to file jointly with the Securities and Exchange Commission (the "SEC") any and all statements on Schedule 13D or Schedule 13G and Forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Beryl Capital Management, LLC, a Delaware limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

     

     

    Dated: April 1, 2024

     

    BERYL CAPITAL MANAGEMENT LLC  

    BERYL CAPITAL MANAGEMENT LP

     

          By: Beryl Capital Management LLC
            General Partner
    By: /s/ Andrew Nelson      
      Andrew Nelson     By: /s/ Andrew Nelson
      Chief Operating Officer and CFO       Andrew Nelson
            Chief Operating Officer and CFO
    BERYL CAPITAL PARTNERS II LP    
         
    By: Beryl Capital Management LP   /s/ David A. Witkin
    General Partner   David A. Witkin
         
    By: Beryl Capital Management LLC    
    General Partner    
         
    By:/s/ Andrew Nelson    
    Andrew Nelson    
    Chief Operating Officer    

     

     

    Get the next $SCTL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SCTL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SCTL
    SEC Filings

    See more
    • SEC Form 15-12G filed by Societal CDMO Inc.

      15-12G - Societal CDMO, Inc. (0001588972) (Filer)

      4/18/24 3:27:56 PM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Societal CDMO Inc.

      EFFECT - Societal CDMO, Inc. (0001588972) (Filer)

      4/12/24 12:15:06 AM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Societal CDMO Inc.

      EFFECT - Societal CDMO, Inc. (0001588972) (Filer)

      4/12/24 12:15:10 AM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCTL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Arens Mathew Paul closing all direct ownership in the company (SEC Form 4)

      4 - Societal CDMO, Inc. (0001588972) (Issuer)

      4/8/24 9:37:26 PM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Weisman Wayne returned $80,982 worth of shares to the company (73,620 units at $1.10), closing all direct ownership in the company (SEC Form 4)

      4 - Societal CDMO, Inc. (0001588972) (Issuer)

      4/8/24 9:36:07 PM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reasons Bryan M. returned $80,982 worth of shares to the company (73,620 units at $1.10), closing all direct ownership in the company (SEC Form 4)

      4 - Societal CDMO, Inc. (0001588972) (Issuer)

      4/8/24 9:34:32 PM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCTL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CoreRx, Inc. Completes Acquisition of Societal CDMO, Inc.

      CLEARWATER, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- CoreRx, Inc. ("CoreRx") today announced that it has completed its acquisition of Societal CDMO, Inc. ("Societal CDMO") (NASDAQ:SCTL), a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily focused on small molecule therapeutics. The Offer and the MergerCoreRx's tender offer to acquire all of the issued and outstanding shares of common stock (the "Shares") of Societal CDMO, at a purchase price of $1.10 per share, in cash, without interest and less any applicable tax withholding, expired as scheduled one minute following 11:59 p.m., Eastern Time, on April 5, 20

      4/8/24 4:05:23 PM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CoreRx, Inc. Completes Acquisition of Societal CDMO, Inc.

      CoreRx, Inc. ("CoreRx") today announced that it has completed its acquisition of Societal CDMO, Inc. ("Societal CDMO") (NASDAQ:SCTL), a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily focused on small molecule therapeutics. The Offer and the Merger CoreRx's tender offer to acquire all of the issued and outstanding shares of common stock (the "Shares") of Societal CDMO, at a purchase price of $1.10 per Share, in cash, without interest and less any applicable tax withholding, expired as scheduled one minute following 11:59 p.m., Eastern Time, on April 5, 2024 and was not further extended. The depositary an

      4/8/24 10:10:00 AM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Societal CDMO Enters Into Definitive Agreement to be Acquired by CoreRx, Inc.

      Societal CDMO to be Acquired by CoreRx, Inc. to Create an Enhanced CDMO with Broad Capabilities Spanning Early-Stage Formulation Development through Commercial Manufacturing and Packaging CoreRx to Commence a Tender Offer for all Outstanding Shares of Societal CDMO, Inc. CLEARWATER, Fla. and GAINESVILLE, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. ("Societal CDMO") (NASDAQ:SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it has entered into a definitive agreement with CoreRx, Inc. ("CoreRx") under which CoreR

      2/28/24 4:29:04 PM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCTL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Societal CDMO Inc. (Amendment)

      SC 13D/A - Societal CDMO, Inc. (0001588972) (Subject)

      4/9/24 4:15:44 PM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Societal CDMO Inc.

      SC 13G - Societal CDMO, Inc. (0001588972) (Subject)

      4/1/24 5:03:18 PM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Societal CDMO Inc.

      SC 13D - Societal CDMO, Inc. (0001588972) (Subject)

      3/6/24 5:11:25 PM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCTL
    Financials

    Live finance-specific insights

    See more
    • CoreRx, Inc. Completes Acquisition of Societal CDMO, Inc.

      CLEARWATER, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- CoreRx, Inc. ("CoreRx") today announced that it has completed its acquisition of Societal CDMO, Inc. ("Societal CDMO") (NASDAQ:SCTL), a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily focused on small molecule therapeutics. The Offer and the MergerCoreRx's tender offer to acquire all of the issued and outstanding shares of common stock (the "Shares") of Societal CDMO, at a purchase price of $1.10 per share, in cash, without interest and less any applicable tax withholding, expired as scheduled one minute following 11:59 p.m., Eastern Time, on April 5, 20

      4/8/24 4:05:23 PM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CoreRx, Inc. Completes Acquisition of Societal CDMO, Inc.

      CoreRx, Inc. ("CoreRx") today announced that it has completed its acquisition of Societal CDMO, Inc. ("Societal CDMO") (NASDAQ:SCTL), a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily focused on small molecule therapeutics. The Offer and the Merger CoreRx's tender offer to acquire all of the issued and outstanding shares of common stock (the "Shares") of Societal CDMO, at a purchase price of $1.10 per Share, in cash, without interest and less any applicable tax withholding, expired as scheduled one minute following 11:59 p.m., Eastern Time, on April 5, 2024 and was not further extended. The depositary an

      4/8/24 10:10:00 AM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cingulate Inc. Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update

      Phase 3 Trial Initiation for Lead ADHD Candidate CTx-1301 in December 2022 Executed Manufacturing Agreement with Societal CDMO 2022 Psych Congress Presentation Demonstrated Ability of Anxiety Candidate CTx-2103 to Deliver a Single Administration of Triple-Release Buspirone KANSAS CITY, Kan., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended September 30, 2022 and provided a clinical and business update. Highlights include

      11/14/22 6:45:00 AM ET
      $CING
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCTL
    Leadership Updates

    Live Leadership Updates

    See more
    • Societal CDMO Announces Appointment of Matt Arens to Board of Directors

      SAN DIEGO and GAINESVILLE, Ga., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. ("Societal CDMO"; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the appointment of Matt Arens to the company's board of directors. Mr. Arens has more than 25 years of experience as a successful investment professional identifying innovative life science companies with high growth potential. For the past 15 years, he solely has managed dedicated health care portfolios. Mr. Arens currently serves as chief executive officer and senior po

      8/23/23 4:04:35 PM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Societal CDMO Appoints Elena Cant to Board of Directors

      SAN DIEGO and GAINESVILLE, Ga., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. ("Societal CDMO"; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the appointment of Elena Cant to the company's board of directors. Ms. Cant has more than 20 years of diverse business experience ranging across various functions including corporate development, business operations and strategy, marketing, commercial, manufacturing, and research and development. She has an impressive track record of establishing and growing functional groups,

      9/8/22 7:00:00 AM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care